Age 12–45 males with FXS with a molecular genetic confirmation FMR1 >200 CGG repetitions needed for clinical trials of new drug zatolmilast.
Tetra Therapeutics is conducting a two randomized, placebo-controlled studies of BPN14770 (zatolmilast) to learn about the experimental drug’s safety and efficacy. Both trials will be followed by an open label extension study. If results are positive, Tetra will be seeking approval of the drug with the FDA.
About the Study
Who can participate?
Males ages 12–45 may be eligible to participate with a molecular genetic confirmation of FXS: FMR1 >200 CGG repetitions.
What will happen in the study?
If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks.
The following is a list of some of the study procedures that will happen during the study:
- Participant cognitive and behavior testing
- Blood draws
- Parent/caregiver questionnaires
For more information, check out Tetra’s study flyer or visit Tetra’s website.
What are the good things that can happen from this research?
Potential benefits are improvement in cognitive (language and vocabulary) function and improvement in daily activities/behavior.
What are the bad things that can happen from this research?
Potential drug side effects include mild nausea and diarrhea.
There may be other risks that we do not know about yet.
Will I or my child be paid to complete this study?
Participants receive $50 per visit (6).
Travel reimbursement is available for eligible families.
Who can I contact for more information about this study?
There will be several sites across the U.S. Complete the contact form below to be notified when the site nearest you opens!
Interested in Participating?
Our Most Recent Opportunities
Study: Autonomic and Sensory Functioning in Infants with FMR1 Conditions
Dr. Jane Roberts and the research staff at the Neurodevelopmental Disorders Laboratory at USC are conducting a research study to learn about the development of infants with Fragile X syndrome and Fragile X premutation over the first few years of life.
Survey: Research experiences in Fragile X Families
The Brain and Biomarker Lab at the University of Oklahoma is conducting a survey to learn about experiences with research, particularly biomedical research, in families with Fragile X syndrome (FXS).
Study: Language Study for Children and Adolescents with Fragile X syndrome
Researchers at the University of Wisconsin-Madison and the University of Massachusetts-Amherst are conducting a study to learn about links between learning and language in Fragile X syndrome.
Survey: Fragile X Nutrition Survey
The University of Wisconsin-Madison is conducting a survey to learn about associations between infant feeding and neurodevelopment in children with Fragile X syndrome.
Clinical Trial: Phase 2B/3 Studies of BPN14770 in Fragile X syndrome
Tetra Therapeutics is conducting a two randomized, placebo-controlled studies of BPN14770/zatolmilast to learn about the experimental drug’s safety and efficacy for males ages 12-45.
Survey: Developing a Gold Standard for Tracking Adult Functional Outcomes in Developmental Disabilities (AFS Study)
University of Pittsburgh is conducting this research to develop the Adult Functioning Scale (AFS), a new survey being designed to capture outcomes in the areas of social functioning, employment, independence, and satisfaction for individuals with various developmental disorders.